Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
20.67
Dollar change
-0.14
Percentage change
-0.67
%
IndexRUT P/E- EPS (ttm)-1.84 Insider Own6.50% Shs Outstand49.04M Perf Week-11.74%
Market Cap1.03B Forward P/E- EPS next Y-2.53 Insider Trans-45.95% Shs Float46.59M Perf Month-25.33%
Income-70.80M PEG- EPS next Q-0.39 Inst Own96.13% Short Float14.12% Perf Quarter-14.34%
Sales46.02M P/S22.38 EPS this Y3.13% Inst Trans-0.29% Short Ratio6.46 Perf Half Y153.31%
Book/sh5.43 P/B3.81 EPS next Y-43.57% ROA-26.44% Short Interest6.58M Perf Year625.26%
Cash/sh6.64 P/C3.11 EPS next 5Y- ROE-39.04% 52W Range2.72 - 30.99 Perf YTD-10.56%
Dividend Est.- P/FCF- EPS past 5Y29.57% ROI-26.10% 52W High-33.30% Beta1.66
Dividend TTM- Quick Ratio5.39 Sales past 5Y74.19% Gross Margin89.93% 52W Low659.93% ATR (14)1.50
Dividend Ex-Date- Current Ratio5.45 EPS Y/Y TTM32.92% Oper. Margin-163.13% RSI (14)33.56 Volatility5.07% 6.65%
Employees121 Debt/Eq0.02 Sales Y/Y TTM11.14% Profit Margin-153.84% Recom1.20 Target Price45.11
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q71.25% Payout- Rel Volume1.12 Prev Close20.81
Sales Surprise57.23% EPS Surprise32.15% Sales Q/Q33.18% EarningsMar 07 BMO Avg Volume1.02M Price20.67
SMA20-11.80% SMA50-19.01% SMA20038.56% Trades Volume1,143,788 Change-0.67%
Date Action Analyst Rating Change Price Target Change
Jan-22-24Initiated JP Morgan Overweight $35
Nov-02-23Initiated Mizuho Buy $20
Apr-21-23Initiated Robert W. Baird Outperform $33
Jul-07-22Initiated Chardan Capital Markets Buy $21
Mar-01-21Initiated Cowen Outperform $25
Jan-28-21Initiated Cantor Fitzgerald Overweight $22
Apr-06-20Downgrade B. Riley FBR Buy → Neutral $4 → $1
Nov-04-19Resumed Laidlaw Buy $5
Sep-12-19Initiated Guggenheim Buy
Mar-18-24 07:00AM
Mar-15-24 01:00PM
Mar-08-24 09:31AM
Mar-07-24 09:39PM
01:25PM
12:53PM Loading…
12:53PM
09:30AM
07:20AM
07:00AM
Mar-04-24 07:00AM
Feb-29-24 10:00AM
08:50AM
07:00AM
04:19AM
Feb-27-24 07:00AM
07:00AM Loading…
Feb-16-24 07:00AM
Feb-15-24 12:00PM
Feb-13-24 09:55AM
08:50AM
Feb-03-24 04:20PM
Jan-31-24 07:00AM
Jan-29-24 11:02PM
Jan-25-24 11:51PM
Jan-24-24 07:01PM
Jan-16-24 07:00AM
Jan-11-24 07:14PM
Jan-10-24 07:00AM
Dec-20-23 07:00AM
Dec-18-23 07:00AM
Dec-13-23 12:45PM
12:00PM Loading…
Dec-11-23 12:00PM
Dec-08-23 04:01PM
09:55AM
08:50AM
Dec-07-23 01:07PM
Dec-05-23 08:18PM
09:18AM
Dec-04-23 04:06PM
11:37AM
07:00AM
06:19AM
Nov-21-23 09:55AM
Nov-16-23 07:00AM
Nov-02-23 07:04PM
Nov-01-23 09:33AM
07:06AM
07:00AM
Oct-31-23 07:00AM
Oct-30-23 07:00AM
Oct-25-23 07:00AM
Oct-16-23 07:00AM
Sep-18-23 07:00AM
Sep-11-23 03:20PM
07:00AM
Aug-30-23 07:00AM
Aug-23-23 07:34PM
Aug-16-23 07:00AM
Aug-09-23 07:00AM
Aug-02-23 08:35AM
07:30AM
07:00AM
Jul-27-23 07:00AM
Jul-26-23 07:00AM
Jul-17-23 07:00AM
Jul-10-23 07:35PM
07:00AM
Jun-05-23 07:00AM
May-31-23 07:00AM
May-18-23 10:29PM
09:02AM
07:00AM
May-16-23 07:00AM
May-14-23 08:19AM
May-03-23 03:44PM
07:18AM
07:00AM
Apr-26-23 07:00AM
Apr-20-23 04:17AM
Apr-17-23 07:00AM
06:28AM
Mar-27-23 07:00AM
Mar-20-23 07:00AM
Mar-15-23 02:43AM
Mar-09-23 09:35AM
Mar-06-23 09:48AM
Mar-04-23 07:07AM
Mar-03-23 01:34AM
Mar-02-23 09:55AM
09:01AM
07:00AM
Feb-27-23 08:00AM
07:00AM
Feb-23-23 07:00AM
Feb-16-23 07:00AM
Jan-23-23 07:00AM
Jan-17-23 07:00AM
Jan-11-23 10:48AM
Jan-05-23 07:00AM
Jan-04-23 07:00AM
Dec-16-22 04:01PM
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elston GeorgeChief Financial OfficerFeb 09 '24Option Exercise0.0010,800046,799Feb 13 05:38 PM
Jones David ScottSVP & Chief Commercial OfficerFeb 09 '24Option Exercise0.009,967048,572Feb 13 05:38 PM
Paggiarino Dario A.Chief Medical OfficerFeb 09 '24Option Exercise0.0010,800047,305Feb 13 05:39 PM
Lurker NancyExecutive Vice ChairFeb 09 '24Option Exercise0.0037,5340172,975Feb 13 05:40 PM
Duker Jay S.President and CEOFeb 09 '24Option Exercise0.0011,967055,453Feb 13 05:37 PM
Jones David ScottSVP & Chief Commercial OfficerFeb 02 '24Option Exercise11.472092,39738,171Feb 05 05:15 PM
Jones David ScottSVP & Chief Commercial OfficerFeb 02 '24Sale28.492095,95437,962Feb 05 05:15 PM
Paggiarino Dario A.Chief Medical OfficerJan 26 '24Option Exercise13.0649,325644,04785,830Jan 30 04:53 PM
Jones David ScottSVP & Chief Commercial OfficerJan 26 '24Option Exercise6.8226,017177,39863,979Jan 29 05:54 PM
Paggiarino Dario A.Chief Medical OfficerJan 26 '24Sale25.6649,3251,265,53936,505Jan 30 04:53 PM
Jones David ScottSVP & Chief Commercial OfficerJan 26 '24Sale25.3826,017660,37037,962Jan 29 05:54 PM
Paggiarino Dario A.Chief Medical OfficerJan 25 '24Option Exercise13.026007,80937,105Jan 29 05:51 PM
Jones David ScottSVP & Chief Commercial OfficerJan 25 '24Option Exercise8.086004,84838,562Jan 26 05:03 PM
Jones David ScottSVP & Chief Commercial OfficerJan 25 '24Sale25.0060015,00037,962Jan 26 05:03 PM
Paggiarino Dario A.Chief Medical OfficerJan 25 '24Sale25.0060015,00036,505Jan 29 05:51 PM
Paggiarino Dario A.Chief Medical OfficerJan 24 '24Option Exercise13.0111,251146,42647,756Jan 25 06:26 PM
Jones David ScottSVP & Chief Commercial OfficerJan 24 '24Option Exercise8.0411,30090,82249,262Jan 26 05:03 PM
Lurker NancyExecutive Vice ChairJan 24 '24Sale24.9829,956748,250135,441Jan 25 06:24 PM
Jones David ScottSVP & Chief Commercial OfficerJan 24 '24Sale25.0111,300282,62137,962Jan 26 05:03 PM
Paggiarino Dario A.Chief Medical OfficerJan 24 '24Sale25.0111,251281,41536,505Jan 25 06:26 PM
Paggiarino Dario A.Chief Medical OfficerJan 23 '24Option Exercise13.045,13566,95441,640Jan 25 06:26 PM
Jones David ScottSVP & Chief Commercial OfficerJan 23 '24Option Exercise7.549006,79038,862Jan 24 04:50 PM
Paggiarino Dario A.Chief Medical OfficerJan 23 '24Sale25.005,135128,37536,505Jan 25 06:26 PM
Lurker NancyExecutive Vice ChairJan 23 '24Sale24.975,044125,950165,397Jan 25 06:24 PM
Jones David ScottSVP & Chief Commercial OfficerJan 23 '24Sale25.0090022,50037,962Jan 24 04:50 PM
Jones David ScottSVP & Chief Commercial OfficerJan 22 '24Option Exercise10.3434,166353,35972,128Jan 24 04:50 PM
Jones David ScottSVP & Chief Commercial OfficerJan 22 '24Sale22.6234,166772,69137,962Jan 24 04:50 PM
Cormorant Asset Management, LP10% OwnerJan 11 '24Buy19.75750,00014,812,5006,893,235Jan 11 04:00 PM
Ocumension TherapeuticsDirectorJan 11 '24Sale19.451,910,50037,159,225100,221Jan 16 06:55 PM
Liu YeDirectorJan 11 '24Sale19.451,910,50037,159,225100,221Jan 16 06:01 PM
Cormorant Asset Management, LP10% OwnerJan 09 '24Buy21.32105,0002,238,6006,143,235Jan 11 04:00 PM
Paggiarino Dario A.Chief Medical OfficerJan 08 '24Option Exercise3.2622,91374,69659,418Jan 10 04:53 PM
Paggiarino Dario A.Chief Medical OfficerJan 08 '24Sale21.1322,913484,12436,505Jan 10 04:53 PM
Lurker NancyExecutive Vice ChairJan 06 '24Option Exercise0.0075,1330193,484Jan 09 09:17 PM
Pine Michael CraigChief Corp Dev.&Strat. OfficerJan 06 '24Option Exercise0.0015,285019,628Jan 09 09:11 PM
Jones David ScottSVP & Chief Commercial OfficerJan 06 '24Option Exercise0.0015,285042,109Jan 09 09:09 PM
Duker Jay S.President and CEOJan 06 '24Option Exercise0.0020,793050,014Jan 09 09:07 PM
Elston GeorgeChief Financial OfficerJan 06 '24Option Exercise0.0015,285040,219Jan 09 09:04 PM
Paggiarino Dario A.Chief Medical OfficerJan 06 '24Option Exercise0.0015,285040,992Jan 09 09:28 PM
Paggiarino Dario A.Chief Medical OfficerDec 13 '23Option Exercise10.131,45814,77027,165Dec 15 05:14 PM
Paggiarino Dario A.Chief Medical OfficerDec 13 '23Sale20.001,45829,16025,707Dec 15 05:14 PM
Cormorant Asset Management, LP10% OwnerDec 08 '23Buy17.00588,2359,999,9956,038,235Dec 12 04:52 PM
Ocumension TherapeuticsDirectorDec 06 '23Sale18.41266,2424,901,5152,010,721Dec 07 09:21 PM
Liu YeDirectorDec 06 '23Sale18.41266,2424,901,5152,010,721Dec 07 09:03 PM
Liu YeDirectorDec 05 '23Sale19.91733,75814,609,1222,276,963Dec 07 09:03 PM
Ocumension TherapeuticsDirectorDec 05 '23Sale19.91733,75814,609,1222,276,963Dec 07 09:21 PM
Pine Michael CraigChief Corp Dev.&Strat. OfficerDec 04 '23Option Exercise12.6245,000567,90050,343Dec 06 05:20 PM
Paggiarino Dario A.Chief Medical OfficerDec 04 '23Option Exercise10.1330,625310,23156,332Dec 06 05:19 PM
Cormorant Asset Management, LP10% OwnerDec 04 '23Buy21.821,919,05741,874,1515,450,000Dec 06 04:39 PM
Pine Michael CraigChief Corp Dev.&Strat. OfficerDec 04 '23Sale22.0045,000990,0005,343Dec 06 05:20 PM
Paggiarino Dario A.Chief Medical OfficerDec 04 '23Sale22.0030,625673,75025,707Dec 06 05:19 PM
Lurker NancyExecutive Vice ChairDec 04 '23Sale20.7620,000415,200170,559Dec 06 05:18 PM
EW Healthcare Partners, L.P.10% OwnerSep 01 '23Sale9.9020,000197,9823,490,921Sep 06 05:14 PM
EW Healthcare Partners, L.P.10% OwnerAug 31 '23Sale10.2478,495804,0613,510,921Sep 01 04:51 PM
EW Healthcare Partners, L.P.10% OwnerAug 30 '23Sale10.9260,976666,1473,589,416Sep 01 04:51 PM
EW Healthcare Partners, L.P.10% OwnerAug 29 '23Sale10.7587,854944,2253,650,392Aug 30 05:46 PM
EW Healthcare Partners, L.P.10% OwnerAug 28 '23Sale11.7160,858712,6533,738,246Aug 30 05:46 PM
EW Healthcare Partners, L.P.10% OwnerAug 25 '23Sale11.0084,656931,4793,799,104Aug 28 06:32 PM
EW Healthcare Partners, L.P.10% OwnerAug 24 '23Sale14.62139,2802,036,0933,883,760Aug 28 06:32 PM
EW Healthcare Partners, L.P.10% OwnerAug 23 '23Sale13.05121,1031,580,9154,023,040Aug 24 05:30 PM
EW Healthcare Partners, L.P.10% OwnerAug 22 '23Sale14.6246,778683,8344,144,143Aug 24 05:30 PM
Zaderej Karen L.DirectorJul 11 '23Option Exercise0.002,00002,000Jul 12 06:51 PM
ADAMIS ANTHONY PDirectorJun 23 '23Option Exercise0.002,00002,000Jun 26 05:10 PM
Liu YeDirectorMay 30 '23Sale6.00163,010,721May 31 05:22 PM